Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal
Executive Summary
Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14
You may also be interested in...
GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company
GSK Gains Vaccine Adjuvant Technology With $300 Mil. Corixa Acquisition
GlaxoSmithKline will expand Corixa's vaccine adjuvant manufacturing capacity following the $300 mil. acquisition of the biotech company
Pfizer Sales Force Stays: Changes Include “Modest” Cuts, No Lay-Offs
Pfizer is not planning dramatic cuts in its sales force over the next three years - and the withdrawal of the COX-2 inhibitor Bextra is not likely to affect that plan